Drug Trial Radar · NCT04810611
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
Last checked: Nov 20, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
33
Actual
Start
Jun 18, 2021
Primary completion
Apr 19, 2024
Study completion Apr 19, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.
Conditions
- Myelodysplastic Syndromes
Interventions
MBG453Drug
Anti-TIM3 monoclonal antibody
NIS793Drug
Anti-TGF-β monoclonal antibody
canakinumabDrug
Anti-IL-1β monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose interruption reductionTime frame: 30 Months
- Incidence of DLTsTime frame: 30 Months
- Dose intensityTime frame: 30 Months
- AE and SAE incidenceTime frame: 30 months
Locations
13 sites in 7 countries. Site status is shown where the registry gives one.
City Of Hope National Med Center Oncology
Duarte, California
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Massachusetts General Hospital .
Boston, Massachusetts
The Ohio State University Wexner Medical Center .
Columbus, Ohio
MD Anderson Cancer Center/University of Texas MD Anderson
Houston, Texas
Novartis Investigative Site
Prahran, Victoria, Australia
Novartis Investigative Site
Tel Aviv, Israel
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Salamanca, Castille and León, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.